These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 12322721)

  • 1. Abbott Laboratories Consent Decree and individual responsibility under the Federal Food, Drug, and Cosmetic Act.
    Blumberg EM
    Food Drug Law J; 2000; 55(1):145-9. PubMed ID: 12322721
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of Abbott's consent decree on clinical laboratories.
    Assarian GS
    MLO Med Lab Obs; 2000 Sep; 32(9):56-8. PubMed ID: 11184639
    [No Abstract]   [Full Text] [Related]  

  • 3. Manufacturing misdeeds cost Abbott record-breaking payment.
    Lewis C
    FDA Consum; 2000; 34(3):38-9. PubMed ID: 11521253
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceutical industry wins "round one" in protections against product liability claims.
    Gatty B
    Hosp Formul; 1995 Apr; 30(4):238, 237. PubMed ID: 10141868
    [No Abstract]   [Full Text] [Related]  

  • 5. Medical device and Laboratory Product Problem Reporting Program (PRP).
    AANA J; 1979 Feb; 47(1):5. PubMed ID: 442931
    [No Abstract]   [Full Text] [Related]  

  • 6. The authority of a court to order disgorgement for violations of the Current Good Manufacturing Practices requirement of the Federal Food, Drug, and Cosmetic Act.
    King E; Walsh EM
    Food Drug Law J; 2003; 58(2):149-68. PubMed ID: 12866550
    [No Abstract]   [Full Text] [Related]  

  • 7. Litigation plays protective role--and is part of the problem.
    Kennett JD
    Mo Med; 2007; 104(1):12-3. PubMed ID: 17410818
    [No Abstract]   [Full Text] [Related]  

  • 8. Statutory interpretation--federal Food, Drug, and Cosmetic Act--Third Circuit holds that the FDA can obtain restitution on behalf of consumers--United States v. Lane Labs-USA Inc., 427 F.3d 219 (3d Cir. 2005).
    Harv Law Rev; 2006 Jun; 119(8):2636-43. PubMed ID: 16830436
    [No Abstract]   [Full Text] [Related]  

  • 9. Laboratory controls--an FDA investigator's viewpoint.
    Avallone HL
    J Parenter Sci Technol; 1986; 40(5):178-82. PubMed ID: 3794896
    [No Abstract]   [Full Text] [Related]  

  • 10. Can the Food and Drug Administration ensure that our pharmaceuticals are safely manufactured?
    Hubbard WK
    Arch Intern Med; 2009 Oct; 169(18):1655-6. PubMed ID: 19822821
    [No Abstract]   [Full Text] [Related]  

  • 11. Retesting and laboratory investigations.
    Davis JS
    J Pharm Sci Technol; 1994; 48(3):107-9. PubMed ID: 8069512
    [No Abstract]   [Full Text] [Related]  

  • 12. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
    DerGurahian J
    Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
    [No Abstract]   [Full Text] [Related]  

  • 13. Authorized generics.
    Glass G
    Nat Rev Drug Discov; 2005 Dec; 4(12):953-4. PubMed ID: 16370080
    [No Abstract]   [Full Text] [Related]  

  • 14. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality control practices and preferences in today's clinical laboratory. A report for government regulators, decision makers, and advisors.
    Cooper WG
    MLO Med Lab Obs; 1997 Jun; 29(6):56-7, 60, 62-5. PubMed ID: 10173036
    [No Abstract]   [Full Text] [Related]  

  • 16. Validation--mission completed?
    Sharp J
    J Parenter Sci Technol; 1993; 47(1):2-3. PubMed ID: 8445494
    [No Abstract]   [Full Text] [Related]  

  • 17. Bitter medicine.
    Simons J
    Fortune; 2002 Oct; 146(7):169-70, 172, 174. PubMed ID: 12408039
    [No Abstract]   [Full Text] [Related]  

  • 18. Universal Management, Abbott, Wyeth, Shering-Plough, and ... : restitution and disgorgement find another home at the Food and Drug Administration.
    Blumberg EM
    Food Drug Law J; 2003; 58(2):169-90. PubMed ID: 12866551
    [No Abstract]   [Full Text] [Related]  

  • 19. Wyeth Pharmaceutical's perspective on vaccine production.
    Stiles GL
    Md Med; 2005; 6(1):22-3. PubMed ID: 15869103
    [No Abstract]   [Full Text] [Related]  

  • 20. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.